Exelixis | EXEL - Należności Handlowe





Należności Handlowe Zmiana Data
Acadia Pharmaceuticals USD 166.33M 17.95M 2026-06
Agios Pharmaceuticals USD 16.13M 5.56M 2026-03
Akebia Therapeutics USD 47.03M 19.19M 2025-12
Amgen USD 10.23B 1.09B 2026-06
AstraZeneca USD 18.86B 972M 2026-06
Bayer EUR 18.7B 146M 2026-06
BioMarin Pharmaceutical USD 1.06B 157.13M 2026-06
Bristol-Myers Squibb USD 13.83B 535M 2026-06
Cytokinetics USD 6.83M 10.94M 2026-03
Eisai JPY 253.13B 26.12B 2026-06
Eli Lilly USD 23.48B 2.3B 2026-06
Exelixis USD 322.21M 6.73M 2026-06
Genmab DKK 1.22B 192M 2026-06
Glaxosmithkline GBP 10.49B 40.6M 2026-03
Incyte USD 1.13B 73.7M 2026-06
Ionis Pharmaceuticals USD 58.84M 15.16M 2026-06
MacroGenics USD 10.42M 2.95M 2026-03
Merck USD 12.21B 435M 2026-03
Moderna USD 17M 54M 2026-06
Nektar Therapeutics USD 3.6M 1.82M 2026-03
Neurocrine Biosciences USD 887M 118.9M 2026-06
Novartis USD 9.85B 252M 2026-06
Pfizer USD 16.19B 19M 2026-06
Puma Biotechnology USD 28.1M 3.52M 2024-06
Sanofi EUR 482M 85M 2026-03
Takeda JPY 956.14B 79.79B 2026-06
Ultragenyx Pharmaceutical USD 60M 98M 2026-03
Xencor USD 42.23M 30.23M 2026-06